Stomach
- (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic,
Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients
with Advanced Solid Tumors
- (106-19) A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination
Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma
- (107-19) A Study of TRK-950 in Combinations With Anti-Cancer Treatment
Regimens in Patients With Advanced Solid Tumors
- (114-19) A Phase 1, open label, first-in-human study of TR1801-ADC, an
antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met
-
(155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics
and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors
and C-Met Dysregulation
- (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity
of ASTX029 in Subjects With Advanced Solid Tumors
-
(180-18) AO-176 in Multiple Solid Tumor Malignancies
- (187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
- (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal
Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1
Monoclonal Antibody, in Subjects with Advanced Cancer
-
(189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With
Metastatic Solid Tumors
- (205-19) Study to Assess AFM24 in Advanced Solid Cancers
- (221-19) Study of GNX102 in Patients With Advanced Solid Tumors
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.